ClinicalTrials.gg
RecruitingNCT06555419PIERRE-PKUpdated Sep 3, 2026

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

A Phase 1 interventional study of Nusinersen and ThecaFlex DRx System in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 21 sites in 7 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing nusinersen in Muscular Atrophy, Spinal — 3 open to participants now, 4 under way, 2 of them phase 3. nusinersen · Muscular Atrophy, Spinal.

Planned enrollment
6th of 19
78 · median 34
Started
2025
the only one that year
Phase 1
5 of 19
1 open now
Registered
17th of 19
by date
Lead sponsor
15 of 19
Biogen

Among the 19 studies testing nusinersen in Muscular Atrophy, Spinal, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 1, and was the 17th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

3 of the 19 studies testing nusinersen in Muscular Atrophy, Spinal are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nusinersen

nusinersen: first FDA approval 2016 (SPINRAZA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nusinersen in Muscular Atrophy, Spinal, or all of them as a file.
02

Study summary

In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ThecaFlex DRx system is an investigational implantable medical device developed by Alcyone Therapeutics, Inc. It consists of a catheter, which is a flexible tube, connected to a port which is placed under the skin. Alcyone Therapeutics, Inc. has an ongoing study called PIERRE to test the ThecaFlex DRx system. Participants with spinal muscular atrophy (SMA) in the PIERRE study may be enrolled in the PIERRE-PK study.

The main goal of the PIERRE-PK study is to learn how the body processes nusinersen when given by the ThecaFlex DRx system compared to a lumbar puncture. The main questions researchers want to answer are:

  • What is the highest amount of nusinersen found in the blood after dosing?
  • How much nusinersen is found in the blood over the first 24 hours after dosing?

The PIERRE-PK study will be done as follows:

  • Participants will be screened to check if they can join the study. The screening period will be up to 30 days for this study and may overlap with the PIERRE study.
  • Participants will join 1 of 2 groups based on their ongoing nusinersen treatment. One group will be receiving 12 mg doses of nusinersen. The other group will be receiving 28 mg doses of nusinersen.
  • Participants will first receive a dose of nusinersen by lumbar puncture.
  • The ThecaFlex DRx system will be implanted after the lumbar puncture, as part of the PIERRE study.
  • Participants will receive a dose of nusinersen by the ThecaFlex DRx system, as part of the PIERRE study. This dose will be a regular maintenance dose that happens about 4 months after their first dose in this study.
  • Researchers will take blood samples before and after each dose. The last blood sample will be taken 24 hours after the dose.
  • The total study duration for each participant in the PIERRE-PK study will be approximately 5 months. This period will overlap with the participant's first 5 months in the PIERRE study.
Read the detailed description

The primary objective of this study is to assess the Pharmacokinetic (PK) profile of nusinersen delivered via standard LP and via the ThecaFlex DRx System in participants with SMA.

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

- Participants must be screened in the PIERRE study to be eligible for enrollment in the PIERRE PK study.

Participants in the 12 mg group

  • Participant must have completed all 4 required 12 mg loading doses as per the approved 12 mg dose regimen.
  • Participant is on regular LP maintenance dosing of nusinersen 12 mg every 4 months, with 120 days ± 14 days between the LP-delivered study dose and the last nusinersen dose prior to study enrollment.

Participants in the 28 mg group

  • Participant must have completed 1 or 2 of the 50 mg loading doses as per the approved 50/28 mg dose regimen.
  • Participant is on regular LP maintenance dosing of nusinersen 28 mg every 4 months, with 120 days ± 14 days between the LP-delivered study dose and the last nusinersen dose prior to study enrollment.

Key Exclusion Criteria:

  • Ongoing participation or participation within 6 months or 5 half-lives of the agent (whichever is longer) of enrollment in other interventional clinical trials for the treatment of SMA (except for the PIERRE study or interventional clinical trials of myostatin inhibitors [e.g., apitegromab and taldefgrobep alfa]).
  • Participant is naïve to nusinersen treatment.
  • Participant is receiving nusinersen at a dose other than 12 mg or 28 mg.
  • Participant has already undergone implantation of the ThecaFlex DRx system or any other implantable medical device for intrathecal (IT) administration.
  • Participant is pregnant, currently breastfeeding, or intending to become pregnant during the study.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Nusinersen 12 mg Via LP and ThecaFlex DRx System

    Participants will receive a maintenance dose of nusinersen, 12 milligrams (mg) via LP in the PIERRE-PK study, followed by implantation of the ThecaFlex DRx System and the subsequent nusinersen 12 mg maintenance dose via the system in the PIERRE study.

    Drug: Nusinersen · Device: ThecaFlex DRx System

  • Experimental
    Nusinersen 28 mg Via LP and ThecaFlex DRx System

    Participants will receive a maintenance dose of nusinersen, 28 mg via LP in the PIERRE-PK study, followed by implantation of the ThecaFlex DRx System and the subsequent nusinersen 28 mg maintenance dose via the system in the PIERRE study.

    Drug: Nusinersen · Device: ThecaFlex DRx System

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BIIB058

  • DeviceThecaFlex DRx System

    Implanted as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx System

    Time frame: Pre-dose and at multiple time points post-dose over 4 months

  2. Area Under the Plasma Concentration-Time Curve From Zero Time to 24 Hours After Intrathecal Administration (AUC0-24h) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx System

    Time frame: Pre-dose and at multiple time points post-dose over 4 months

07

Study locations

19 of 21 sites recruiting
  • St. Joseph's Hospital and Medical Center - Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
    Recruiting
    • · Contact602-406-6262
    • Shafeeq Ladha · Principal investigator
  • Children's Hospital of Orange County
    Orange, California 92868, United States
    Recruiting
    • · Contact714-509-3605
    • Julian Thomas · Principal investigator
  • Stanford University Medical Center | Department of Neurology_Palo Alto
    Palo Alto, California 94304, United States
    Recruiting
    • · Contact650-723-5152
    • John Day · Principal investigator
  • Nemours Children's Hospital, Orlando
    Orlando, Florida 32827, United States
    Recruiting
    • · Contact407-650-7715
    • Abdul Hamid Omer · Principal investigator
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611-2605, United States
    Recruiting
    • · Contact312-227-3550
    • Nancy Kuntz · Principal investigator
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • · Contact617-355-8036
    • Basil T Darras · Principal investigator
  • Helen DeVos Children's Hospita
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • · Contact616-391-2241
    • Jena Krueger · Principal investigator
  • Milton S. Hershey Medical Center | Pennsylvania State University_Hershey
    Hershey, Pennsylvania 17033, United States
    Recruiting
    • · Contact717-232-5443
    • Dustin Paul · Principal investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • · Contact215-590-3174
    • Patrick Cahill · Principal investigator
  • Texas Childrens Hospital Houston
    Houston, Texas 77030, United States
    Recruiting
    • · Contact832-822-1750
    • David Bauer · Principal investigator
  • Stacey Hall Developmental Pediatrics
    Charlottesville, Virginia 22903, United States
    Recruiting
    • · Contact434-924-8184
    • Rebecca J Scharf · Principal investigator
  • Children's Hospital of the King's Daughters_Norfolk
    Norfolk, Virginia 23507, United States
    Recruiting
    • · Contact757-668-7000
    • Crystal Proud · Principal investigator
  • Hôpital Raymond Poincaré
    Garches, Hauts De Seine 92380, France
    Recruiting
    • · Contact+33147104684
    • Marta Gomez · Principal investigator
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
    Recruiting
    • · Contact49 201 7230
    • Tim Hagenacker · Principal investigator
  • Fondazione Serena Onlus - Centro Clinico Nemo_Milano
    Milan, 20162, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 168, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szpital Specjalistyczny im. L.Rydygiera w Krakowie
    Krakow, 31-826, Poland
    Recruiting
    • · Contact48604565621
    • Ryszard Nowak · Principal investigator
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, 93-338, Poland
    Recruiting
    • · Contact+48606989185
    • Przyslo Lukasz · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • · Contact+34917277388
    • Maria Garcia Romero · Principal investigator
  • Hospital Universitari i Politecnic La Fe_Valencia
    Valencia, 46026, Spain
    Recruiting
    • · Contact34 961 24 55 42
    • Juan Francisco Vazquez Costa · Principal investigator
  • Royal Hallamshire Hospital Neurology Department
    Sheffield, South Yorkshire S102JF, United Kingdom
    Recruiting
    • · Contact+441142713708
    • Chanma Hewadduma · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2024
First posted
Aug 15, 2024
StartActual
Jan 16, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06555419
Lead sponsor
Biogen
Collaborators
Alcyone Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Jan 16, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nusinersen

Start the discussion